Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Nuvectis Pharma, a company specializing in innovative oncology treatments, announced that Ron Bentsur, its CEO, will present an overview at the H.C. Wainwright Global Investment Conference.

The event is scheduled for May 24, 2022, at 4:00 PM Eastern Time. A live webcast will be available for approximately 30 days.

Nuvectis's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in preclinical testing.

News Market Reaction – NVCT

-13.46%

-13.46% Session move

In the trading session that priced this news, NVCT declined 13.46%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.

A live webcast of the presentation will be available on the link provided below for approximately 30 days.

Event	H.C. Wainwright Global Investment Conference
Date	May 24, 2022
Time	4:00 PM Eastern Time
Link	https://journey.ct.events/view/1ff8e74f-de55-4aad-bddf-9464a6c02784

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.

For more information, please visit www.nuvectis.com.

Nuvectis Pharma Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact:

Christopher M. Calabrese

LifeSci Advisors

Tel: 917-680-5608

ccalabrese@lifesciadvisors.com

FAQ

When is Nuvectis Pharma's presentation at the H.C. Wainwright Global Investment Conference?

Nuvectis Pharma will present on May 24, 2022, at 4:00 PM Eastern Time.

Where can I watch the Nuvectis Pharma presentation?

The live webcast of the presentation can be viewed at this link: https://journey.ct.events/view/1ff8e74f-de55-4aad-bddf-9464a6c02784.

What is Nuvectis Pharma's focus in oncology?

Nuvectis Pharma focuses on developing innovative precision medicines for serious conditions in oncology.

What drugs are in Nuvectis Pharma's pipeline?

Nuvectis's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in preclinical testing.

Who is the CEO of Nuvectis Pharma?

Ron Bentsur is the Chairman and CEO of Nuvectis Pharma.